WO2004045633A2 - Pharmaceutical composition comprising octreotide microparticles - Google Patents

Pharmaceutical composition comprising octreotide microparticles Download PDF

Info

Publication number
WO2004045633A2
WO2004045633A2 PCT/EP2003/012898 EP0312898W WO2004045633A2 WO 2004045633 A2 WO2004045633 A2 WO 2004045633A2 EP 0312898 W EP0312898 W EP 0312898W WO 2004045633 A2 WO2004045633 A2 WO 2004045633A2
Authority
WO
WIPO (PCT)
Prior art keywords
microparticles
pharmaceutical composition
lactide
glycolide
octreotide acetate
Prior art date
Application number
PCT/EP2003/012898
Other languages
French (fr)
Other versions
WO2004045633A3 (en
Inventor
Olivier Lambert
Michael Ausborn
Holger Petersen
Rolf LÖFFLER
Jean-Daniel Bonny
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32299717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004045633(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0226993A external-priority patent/GB0226993D0/en
Priority claimed from GB0227883A external-priority patent/GB0227883D0/en
Priority to AU2003293700A priority Critical patent/AU2003293700A1/en
Priority to JP2004552645A priority patent/JP2006514927A/en
Priority to KR1020127001817A priority patent/KR101240071B1/en
Priority to CA2501978A priority patent/CA2501978C/en
Priority to EP03789053A priority patent/EP1565161A2/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to KR1020057008892A priority patent/KR101146471B1/en
Priority to BR0316421-7A priority patent/BR0316421A/en
Priority to MXPA05005388A priority patent/MXPA05005388A/en
Publication of WO2004045633A2 publication Critical patent/WO2004045633A2/en
Publication of WO2004045633A3 publication Critical patent/WO2004045633A3/en
Priority to NO20052952A priority patent/NO20052952L/en
Priority to AU2008200018A priority patent/AU2008200018B2/en
Priority to AU2011200966A priority patent/AU2011200966B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • composition comprising microparticles
  • the present invention relates to pharmaceutical compositions, in particular to depot microparticles.
  • Octreotide acetate microparticles for injectable suspension are commercialized as pharmaceutical compositions under the brand name SANDOSTA ⁇ N LAR. These pharmaceutical compositions are indicated for, inter alia, long-term maintenance therapy in acromegalic patients, and treatment of severe diarrhea and flushing associated with malignant carcinoid tumors and vasoactive intestinal peptide tumors (vipoma tumors).
  • the pharmaceutical compositions are normally administered once-a-month.
  • the octreotide is presented as a sterile pharmaceutical composition in a vial which when mixed with a vehicle for suspension such as sterile water becomes a suspension that is administered by an intragluteal injection.
  • the octreotide acetate microparticles are produced from the acetate salt of octreotide which is distributed throughout a biodegradable poly (DL-lactide-co-glycolide)-glucose star polymer (disclosed in e.g. US patent 5,922,682, the contents of which are incorporated herein by reference).
  • the octreotide acetate microparticles are produced according to the teaching of US patent 5,538,739 (the contents of which are incorporated herein by reference) involving use of silicone oil and heptane. Traces of these starting materials may be detected in the final product.
  • octreotide composition based on linear poly (lactide-co-glycolide) in sustained release form for parenteral administration has reached the market.
  • the present invention provides a sustained release formulation of octreotide which is less expensive than the one available on the market and which is more easy to manufacture.
  • the present invention provides commercially acceptable octreotide acetate microparticles produced from linear poly (lactide-co-glycolide), hereinafter referred to as PLG, which have similar pharmacokinetic characteristics to SANDOSTA ⁇ N LAR with acceptable drug loading whilst also of high purity and which may be free from silicone oil and heptane. Accordingly in one aspect the present invention provides i) a pharmaceutical composition comprising octreotide acetate microparticles of linear poly
  • the present invention provides a process for the production of octreotide acetate microparticles, comprising the steps of: a) dissolving or dispersing octreotide acetate in methylene dichloride containing a dissolved linear poly (lactide-co-glycolide) to form a dispersion or a homogeneous solution; b) combining said dispersion with an effective amount of a continuous process medium to form an emulsion that contains said process medium and microdroplets comprising said octreotide acetate, said solvent and said linear poly (lactide-co-glycolide); and c) immediately after the formation of said emulsion, adding all at once said emulsion to an effective amount of an extraction medium to extract said solvent from said microdroplets to form said microparticles.
  • the present invention provides a process for the production of octreotide acetate microparticles, comprising the steps of: a) dispersing octreotide acetate in methylene chloride containing a dissolved linear poly (lactide-co-glycolide) to form a dispersion; b) combining said dispersion with an effective amount of a continuous process medium, to form an emulsion that contains said process medium, e.g water or preferably an aqueous buffered solution with a stabilizing agent, e.g.
  • a stabilizing agent e.g.
  • microdroplets comprising said octreotide acetate, said solvent and said linear poly (lactide-co-glycolide); c) immediately after the formation of said emulsion, adding all at once said emulsion to an effective amount of an extraction medium, e.g. an aqueous phase, e.g. an aqueous solution of a stabilizing agent, e.g. polyvinylalcohol, to extract said solvent from said microdroplets to form said microparticles; and d) collecting and drying the microparticles, e.g. freeze-drying or drying under vacuum.
  • an extraction medium e.g. an aqueous phase, e.g. an aqueous solution of a stabilizing agent, e.g. polyvinylalcohol
  • the present invention provides a process for the production of octreotide acetate microparticles by a multiple emulsion process, the improvement which comprises the steps of: a) dissolving octreotide acetate in an aqueous solution, e.g. water or a buffered aqueous solution, emulsifying the octreotide acetate aqueous solution with methylene chloride containing a dissolved linear poly (lactide-co-glycolide) to form a water in oil emulsion; and b) emulsifying said emulsion with an aqueous solution, e.g. an aqueous solution containing a stabilizing agent, e.g.
  • an extraction medium e.g. an aqueous phase, e.g. an aqueous solution of a stabilizing agent, e.g. polyvinylalcohol, to extract said solvent from said microdroplets to form said microparticles; and d) collecting and drying the microparticles, e.g. freeze-drying or drying under vacuum.
  • an extraction medium e.g. an aqueous phase, e.g. an aqueous solution of a stabilizing agent, e.g. polyvinylalcohol
  • An aqueous solution of octreotide acetate may be used, preferably a water solution, which is then emulsified with the polymer solution to form an emulsion.
  • aqueous solution of a stabilizing agent e.g. polyvinylalcohol
  • a stabilizing agent e.g. polyvinylalcohol
  • octreotide acetate is preferably dissolved in a polar organic solvent miscible with methylene chloride, preferably methanol.
  • the process may be effected as described above.
  • the process medium of processes A, B and C can be, e.g. an aqueous phase, e.g. an aqueous solution of PNA, e.g. an aqueous solution of PNA and optionally at least one buffering salt.
  • the process medium can be saturated with the same organic solvent as used to dissolve the polymer in order to stabilize the formation of the emulsion droplets and avoid a too fast extraction of the polymer solvent from the emulsion droplets.
  • the PLG may be dissolved in any of the solvents suitable for PLG dissolution, e.g. ethylacetate, tetrahydrofurane, acetonitrile, methylene chloride, hexafluoroisopropanol, chloroform, acetone.
  • PLG may be dissolved in methylene chloride at a concentration of from about 1% to about 40%, typically about 2- 2.5% w/v.
  • the suitable polymer solvent when the suitable solvent used to dissolve PLG is miscible with water, the suitable polymer solvent may be removed by extraction from the microparticles with water or with an aqueous solution as described above.
  • Step a) would be identical as described in the processes A, B and C of the invention. But for step b), the dispersion or the solution or the emulsion prepared in step a) is mixed with high shear stress with a suitable quantity of process medium in the ratio of 1 volume of said dispersion or solution of step a) with 10 to up to 50 volumes of continuous medium. Then step c) would consist in hardening the microparticles by solvent evaporation under stirring, e.g. 200 rpm at room temperature with constant evacuation of solvent vapors, for 1 up to 10 hours , e.g.
  • step d) would consist in washing the microparticles, e.g. in water, collecting and drying the microparticles, e.g. freeze-drying or drying under vacuum.
  • the processes may be effected in conventional manner, e.g. high speed stirrers may be used to produce emulsions.
  • concentration of octreotide acetate in polar organic solvent or in aqueous solution is preferably from about 1% to about 20% w/v, preferably about 4 to 10% w/v, more preferably about 4 to 7% w/v, even more preferably about 5% w/v. It is preferred to have a homogeneous solution after mixing of the octreotide with the dissolved linear poly (lactide-co- glycolide).
  • Mixture of up to about 20% v/v of (i) a solution containing methanol with (ii) methylene chloride containing a dissolved linear poly (lactide-co-glycolide), e.g. with the concentration of poly(lactide-co-glycolide) in the organic solvent being not more than 20% w/v), may still result in a homogeneous solution, e.g. up to about 20% v/v of solution (i) in a mixture of (i) + (ii).
  • the weight ratio of component (i) to component (ii) is typically about 1:8.
  • an emulsion may be produced by dispersing the octreotide acetate/PLG - methylene chloride mixture into an aqueous process medium.
  • the continuous phase which is preferably saturated with the polymer solvent, e.g. methylene chloride.
  • the process medium Prior to the addition of the mixture containing the PLG/octreotide to the process medium, the process medium is preferably saturated with the suitable solvent of the polymer, e.g. methylene chloride to reduce extraction of solvent from the microdroplets during formation of the emulsion.
  • the process medium is then mechanically agitated with devices such as homogenizers, propellers or the like, as the PLG/octreotide mixture is added to the process medium.
  • no solvent may be generally evaporated or removed from the microdroplets.
  • the temperature at which the emulsion is formed is not particularly critical, except that it may be within a range that will prevent the methylene chloride from boiling or the process medium from gelling or freezing or the octreotide or PLG from degrading.
  • the time required to form an emulsion is quite short. Generally, emulsions may be formed within 30 seconds to 5 minutes, depending upon the stabilizing agent, if any, used and the method of agitation of the process medium.
  • a stabilizing agent is present.
  • a stabilizing agent for emulsions produced in microparticle processes is present to prevent agglomeration.
  • concentration present may affect the final size of the microparticles.
  • concentration of the emulsion stabilizing excipient in the process medium will be from 0.01% to about 20% w/v depending on the surfactant, the polymer solvent, and the process medium used.
  • the amount of stabilizing agent is preferably from about 0.025 to about l%w/v.
  • Suitable stabilizing agents include:
  • A) polyvinyl pyrrolidone Suitably the molecular weight may vary between 2000 and 20000 daltons. Suitable examples include those commonly known as Povidone K12 F (average molecular weight about 2500 daltons), Povidone K15 (average molecular weight about 8000 daltons) or Povidone K17 (average molecular weight about 10000 daltons).
  • the polyvinyl pyrolidone is present in an amount of from about 0.1 to about 20% w/v, e.g. about 5% w/v.
  • the viscosity may be, e.g. up to 20 cP or mPa s for a 2% aqueous solution or a viscosity of from 8 to 25 mPa s.
  • the degree of substitution is from about ⁇ .5 to about 1.45, e.g. 1.15 to about 1.45, e.g. 0.7.
  • the sodium content is about 5 to about 12%, e.g. 10.5% to about 12%.
  • the polyvinyl alcohol has a molecular weight from about 10000 to about 150000, e.g. from about 10000 to about 90000 daltons, e.g. about 30000 daltons.
  • the polyvinyl alcohol has a low viscosity having a dynamic viscosity of from about 3 to about 9 mPa s when measured as a 4% aqueous solution at 20°C or by DIN 53015.
  • the polyvinyl alcohol may be obtained from hydrolyzing polyvinyl acetate.
  • the content of the polyvinyl acetate is from about 10 to about 90% of the polyvinyl alcohol.
  • the degree of hydrolysis is about 85 to about 89%.
  • the residual acetyl content is about 10 to 12 %.
  • Preferred brands include Mowiol 4-88, Mowiol 8-88 and Mowiol 18-88 available from Clariant AG Switzerland.
  • the polyvinyl alcohol is present in an amount of from about 0.1 to about 5%, e.g. 0.5% w/v.
  • gelatin Preferably, the gelatin is porcine or fish gelatin. Conveniently, the gelatin has a viscosity of about 25 to about 35 cps for a 10% solution at 20°C.
  • pH of a 10% solution is from about 6 to about 7.
  • a suitable brand has a high molecular weight, e.g. Norland high molecular weight fish gelatin obtainable from Norland Products Inc, Cranbury New Jersey USA.
  • the gelatin is present in an amount of from about 0.01 to about 5%, e.g. 0.5 % or 0.05%.
  • polyvinyl alcohol may be used.
  • step c) transferring all of the emulsion immediately to a large volume of process medium or other suitable extraction medium to immediately extract the solvent from the microdroplets in the emulsion forms microparticles of the invention.
  • the process medium containing the organic microdroplets is transferred, as quickly as possible, to an extraction medium so that greater than 20% to 30% of the solvent may be immediately removed from the microdroplets, e.g. within 3 minutes.
  • an extraction medium so that greater than 20% to 30% of the solvent may be immediately removed from the microdroplets, e.g. within 3 minutes.
  • water is used as the extraction medium but other solvents or oils can also be used.
  • salts may be added to the extraction medium to adjust its ionic strength or pH.
  • the amount of extraction medium used may be somewhat critical in that sufficient medium must be present to allow approximately immediate extraction of the solvent out of the microdroplets. Accordingly, the volume of the extraction medium will depend on the solvent used to dissolve the wall material and its solubility in the extraction medium.
  • the volume of the extraction medium should be at least the volume needed to dissolve all of the solvent out of the microdroplets, preferably a volume 10-fold or higher.
  • the added water is at a pH of about 7 or higher. Such pH may be adjusted to increase the encapsulation efficiency of the octreotide in the microparticles of the invention.
  • an aqueous sodium dihydrogen phosphate/disodium hydrogen phosphate buffer solution is present
  • the hardened microparticles may be collected by centrifugation, filtration, or the like.
  • gelatin is not used and is absent in the microparticles of the invention.
  • the lactide may be D, L or mixtures thereof, e.g. racemic DL lactide.
  • Homopolymers e.g. poly(DL-lactide) homopolymers
  • the molecular weight of the homopolymers is from about 7,000 to 25,000 daltons, e.g. 18 000 daltons.
  • the polymer used is poly (DL-lactide-glycolide), herein after referred as PLG.
  • the ratio of lactide to glycolide units in the PLG may vary between wide limits. It is however preferred to have a molar ratio of from 90 to 10 to 40:60 lactide to glycolide units, e.g. (i) 50:50 poly(lactide-glycolide) or (ii) 75:25 poly(lactide-glycolide) or (iii) 65:35 poly(lactide- glycolide).
  • the polymers may be pure poly(lactide-glycolide) polymers or copolymers with other units. Preferably they are pure poly(lactide-glycolide) polymers.
  • the average molecular weight of the PLG is from about 5,000 to about 70,000 daltons, e.g. 13 000, preferably it is from about 30,000 to about 70,000 daltons, especially from about 40,000 to about 60,000 daltons, more especially about 50,000 daltons.
  • the inherent viscosity of the PLG may vary between wide limits. It is however preferred to be in the range from about 0.1 to about 0.8 dL/g, e.g. from about 0.2 to about 0.8 dL/g in hexafluoroisopropanol or preferably chloroform when measured under standard conditions, e.g. 20°C.
  • a preferred example has a viscosity of from 0.45-0.55 dL/g in chloroform.
  • the polymer is amorphous.
  • the linear polymer of the invention is not a star polymer and contains less than 5%, or preferably is free from, star polymers, e.g. a reaction product of a polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 or a reactive derivative thereof and lactic acid or a reactive derivative thereof and glycolic acid or a functional derivative thereof.
  • star polymers e.g. a reaction product of a polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 or a reactive derivative thereof and lactic acid or a reactive derivative thereof and glycolic acid or a functional derivative thereof.
  • the linear polymers of the invention may be produced in conventional manner, e.g. using conventional techniques such as polycondensation and ring-opening of dimers.
  • the production may be, e.g. according to the teachings of US patent 3,773,919 (the contents of which are hereby incorporated herein by reference).
  • the polymer may be a reaction product of lactic acid or a reactive derivative thereof, e.g. D,L-lactide, and glycolic acid or a functional derivative thereof, e.g. glycolide.
  • a suitable catalyst for the production of linear polymers for example zinc oxide, zinc carbonate, basic zinc carbonate, diethyl zinc, organotin compounds, for example stannous octoate (stannous 2-ethylhexanoate), tributylaluminium, titanium, magnesium or barium compounds or litharge.
  • Stannous octoate stannous 2-ethylhexanoate
  • the polymer is preferably obtained from Birmingham Polymers Inc., Birmingham, Alabama, USA.
  • the octreotide acetate may be produced in conventional manner, e.g. as disclosed in US patent
  • the amount of octreotide on or near the surface and hence the initial drug burst may be reduced by briefly washing the microparticles of the invention with water, e.g. including a
  • microparticles of the invention may be dried, e.g. to remove water and other volatiles like methylene chloride.
  • the microparticles of the invention may be subjected, e.g. to:
  • the volatile solvent e.g. methylene chloride
  • aqueous solution preferably a buffered water solution, e.g. potassium/sodium phosphate, optionally under vacuum conditions of the drying process 2.
  • the microparticles of the invention may be purged with nitrogen or another inert gas. If desired the microparticles of the invention may be heated, e.g. from 25 to 55°C, preferably from 48 to 54°C. Duration of the drying period may be, e.g. from 2 hours to 5 days.
  • the present invention provides a process for the production of octreotide acetate microparticles by an emulsion process, which comprises the step of removing volatile solvents, e.g. methylene chloride.
  • the resultant microparticles may be free-flowing powders of spherical particles.
  • microparticles of the invention contain preferably less than 1 % silicone oil, e.g. less than
  • microparticles of the invention include for example less than 0.5%, e.g. less than 0.2%, preferably less than 0.1%, methylene chloride.
  • microparticles of the invention include for example less than 0.05%, e.g. less than 0.03%, preferably less than 0.01% especially less than 0.005% or 0.001%, methanol.
  • microparticles of the invention include for example less than 3%, e.g. less than 1%, less than 0.1% preferably less than 0.05 or 0.01%, especially less than 0.005%, polyvinyl alcohol.
  • microparticles of the invention include for example less than 2%, e.g. less than 1 or 2.%, preferably less than 0.1% heptane, especially less than 0.01% or 0.005% heptane.
  • microparticles of this invention may have, e.g. a size range from about 1 to 250, preferably 10 to 200, especially 10 to 130 microns in diameter.
  • Mean diameters may be, e.g. from 30 to 100 microns, e.g. from 30 to 90 microns, e.g. 80 to 100 microns.
  • the size distribution of the microparticles of the invention has preferably at least one of the following average diameter characteristics:
  • microparticles of the invention 95% or more greater than 10 microns based on the average size distribution as measured by conventional light scattering methods. It is preferred to have a broad size distribution of the microparticles of the invention.
  • microparticles of the invention may exhibit a smooth to rough surface.
  • microparticles of the invention It is preferred to have a smooth surface in the microparticles of the invention.
  • the smoothness may be determined in conventional manner, e.g. by visual determination by electron microscopy.
  • microparticles of the current invention are usually made up of particles of a spherical shape, although microparticles may be irregularly shaped.
  • the surface area varies by about 5% from the corresponding surface area of a sphere.
  • Unit doses may be produced which vary from about 85 to about 115%, e.g. from about 90 to about 110%, or from about
  • the microparticles of the invention are dense rather then porous.
  • the porosity may be determined in conventional manner, e.g. by visual determination by BET-nitrogen-sorption / Hg-porosimetry or electron microscopy, e.g. by observing the diameter and extent of channels in a cut microparticle.
  • microparticles of the invention contain less than 4 %, especially less than 3% and preferably less than 2% total octreotide degradation products.
  • the present invention also provides a pharmaceutical composition comprising microparticles of the invention.
  • the pharmaceutical composition may be in the dry state.
  • the pharmaceutical composition contains a vehicle to facilitate reconstitution.
  • the vehicle preferably comprises from about 1% to 40% of the pharmaceutical composition.
  • the microparticles of the invention may comprise from about at least 90 % of the pharmaceutical composition.
  • a vehicle to facilitate reconstitution may be provided together with the pharmaceutical composition.
  • the vehicle for reconstitution may be provided, e.g. in a separate vial or ampoule or in a separate chamber of a two chamber syringe, e.g. a two chamber syringe consisting of one compartment containing the microparticles and optionally an isotonizing agent, and optionally a surfactant and optionally a viscosity increasing agent, e.g. coated on the microparticles or present as a layer in the compartment containing the microparticles and one compartment containing the vehicle or an aqueous phase, e.g. water for injection, a buffered solution, e.g. a low molarity phosphate buffered solution at physiologic pH, if all the excipients of the vehicle are already in the chamber together with the microparticles, for suspension of the microparticles.
  • a buffered solution e.g. a low molarity phosphat
  • microparticles of the invention are hydrophobic. When using water as a vehicle, the microparticles of the invention will not resuspend and they will float on the top of the aqueous phase. Therefore the problem is to find a vehicle to suspend the microparticles of the invention and suitable for injection.
  • a wetting-agent can be included into the vehicle to improve the capacity of the microparticles of the invention to be suspended in an aqueous medium.
  • the vehicle may contain excipients, e.g. a viscosity-increasing agent and/or a wetting-agent.
  • a vehicle for suspension may comprise a viscosity increasing agent and/or wetting agent as mentioned above and additionally water.
  • a suitable anti-agglomerating agent includes mannitol.
  • Mannitol may also serve as a suitable isotonizing agent.
  • the pharmaceutical composition in the dry state may comprise an anti-agglomerating agent such as mannitol. Preferably, this is present in about2 to 10%, e.g. about 2-5%, e.g. 4% weight/weight of the microparticles in the dry state of the pharmaceutical composition.
  • the total concentration of the isotonizing agent corresponds to the concentration of the isotonizing agent when the microspheres are in suspension in the vehicle.
  • the total concentration of isotonizing agent may be of from 1 to 50 mg/ml, e.g. 4 to 10 mg/ml, e.g. 5 to 8 mg ml, e.g. 6 mg ml.
  • An anti-agglomerating agent can used in the pharmaceutical composition, i.e. the anti-agglomerating agent may be present in the dry state with the micropheres or may be present on the surface of the microspheres.
  • the concentration of said isotonizing agent in the vehicle is calculated to so that the total concentration of isotonizing/anti-agglomerating agent in the vehicle with the microparticles in suspension in said vehicle may be in the range of from 1 to 50 mg ml, e.g. 4 to 10 mg/ml, e.g. 5 to 8 mg/ml, e.g. 6 mg/ml.
  • a suitable viscosity-increasing agent includes carboxymethyl cellulose sodium, herein after referred as NaCMC.
  • NaCMC has a low viscosity. Embodiments may be as described above. Typically, NaCMC has a high molecular weight.
  • the viscosity may be from about 1 to 30 mPa s, e.g. from 10 to about 15 mPa s when measured as a 1% (w/v) aqueous solution at 25°C in a Brookfield LVT viscometer with a spindle 1 at 60 rpm.
  • the degree of substitution is of NaCMC from about 0.7 to about 1.45, e.g. from about 1.15 to about 1.45.
  • the sodium content of NaCMC is from about 5 to about 12%, e.g. about 10.5% to about 12%.
  • NaCMC can be present in this is present in about 0.1-1%, e.g. 0.5% w/v of the vehicle composition.
  • Said suitable viscosity-increasing agent can be present in a concentration of 1 to 30 mg ml in the vehicle, e.g. 7 mg/ml, 10 mg ml.
  • a wetting agent is present.
  • Such wetting agents preferably include non-ionic surfactants.
  • Poloxamers also known as polyoxyethylene polyoxypropylene block copolymers
  • the poloxamers of the invention are solid.
  • the molecular weight is from about 2000 to about 8000 daltons.
  • the degree of polymerization of the ethylene moeity is typically 80 to about 110 units.
  • the degree of polymerization of the propylene moiety is typically 20 to about 60 units.
  • Examples of such compounds suitable for use in accordance with the present invention are those known and commercially available, e.g. under the trade name Pluronic F 68 available from BASF Germany.
  • Pluronic F 68 can be present in the vehicle composition at a concentration of from 0.1 mg/ml to 5 mg ml.
  • Polyoxyethylene-sorbitan-fatty acid esters e.g. mono- and trilauryl, palmityl, stearyl and oleyl esters e.g. of the type known and commercially available under the trade name TWEEN
  • Especially preferred products of this class for use in the pharmaceutical compositions of the invention are the above products TWEEN 20, TWEEN 40 and TWEEN 80.
  • Such wetting agents are preferably present in about 0.01 to about 1% w/v, e.g. 0.1% w/v of the pharmaceutical composition.
  • Said wetting agents may be present in about 0.01 to 5 mg/ml of the vehicle, e.g. 2 mg/ml.
  • the pharmaceutical composition may be stored under aseptic conditions, e.g. in a vial. All steps are conveniently effected under sterile conditions using sterile material, e.g. produced using sterile filters.
  • Microparticles of the present invention may be stored in the form of a powder. If desired a dry pharmaceutical composition and an aqueous medium vehicle for reconstitution may be housed separately in a double chamber syringe. For administration as injection the microparticles are suspended in a suitable vehicle for suspension, e.g. before administration to the patient.
  • the amount of liquid vehicle for suspension is preferably about 0.5 to 5 ml, e.g. 1 to 5 ml, e.g. 1 ml per dose, 2 ml per dose.
  • the liquid may be mixed with the dry pharmaceutical composition just prior to administration.
  • the vehicle according to the present invention comprises a wetting agent in a concentration of 0.1 mg/ml to 5 mg/ml and/or a viscosity-increasing agent present in a concentration of 1 to 30 mg/ml and
  • compositions of the invention provides a pharmaceutical composition
  • compositions of the invention may be administered by intragluteal, intramuscular or subcutaneous injection.
  • the pharmaceutical compositions of the invention administered by injection provide an effective treatment of diseases over an extended period, e.g. over 2 weeks to 6 months, e.g. over 2 weeks to 8 weeks, e.g. over 2 to 6 weeks.
  • the microparticles allow a controlled release of octreotide by diffusion and therefore steady-state levels of the drug are obtained over the extended period.
  • microparticles of the invention may be used for the same indications as known octreotide acetate microparticles.
  • the exact dose of octreotide will depend on a number of factors, including the condition to be treated, the severity of the condition to be treated, the weight of the subject and the duration of therapy.
  • microparticles of the invention used will depend on a number of factors, including the rate of release of octreotide and the desired duration of treatment.
  • the amounts may be determined using standard animal and clinical tests, e.g. bioavailability tests using rabbits, using SANDOSTA ⁇ N LAR as a standard.
  • Octreotide levels may be determined using conventional methods, e.g. gas chromatography or high performance liquid chromatography.
  • gas chromatography or high performance liquid chromatography.
  • 800 ng/1 may be reached from day 21 and last for 4 weeks.
  • octreotide may be any of the following:
  • compositions of the invention preferably include 10, 20 or 30 mg of octreotide.
  • the loading of octreotide in the microparticles of the invention is from about 1 to about 50 %, e.g. 1 to about 50%, e.g. 1 to 7%, e.g. from about 3 to about 7%, typically 4 to 6 %, e.g. 5%.
  • compositions of the invention are useful for the treatment of a disease treatable by octreotide, e.g. acromegaly.
  • the present invention also provides: a) Use of the octreotide for the manufacture of microparticles or pharmaceutical compositions of the invention to be administered to a patient for the treatment of a disease treatable by octreotide, e.g. acromegaly. b) A method of administering of the octreotide, e.g. for the treatment of acromegaly, said method comprising administering to a patient in need of octreotide therapy microparticles or a pharmaceutical composition of the invention.
  • PVA polyvinyl alcohol
  • the PNA is stirred at about 750 rpm by a 2.5 inch impeller (e.g. TEFLON driven by a Fisher Stedi-speed motor).
  • the PVA is also saturated with 7 ml of methylene chloride prior to the addition of the polymer/drug solution. The resulting emulsion is allowed to stir for 7 min.
  • the microparticles are stirred in the deionized water for approximately 30 min and then were collected over 45- ⁇ m mesh size meter and 212- ⁇ m mesh size stainless steel mesh steel sieves arranged in series. The microparticles are rinsed with additional deionized water and allowed to air dry.
  • microparticles of the invention obtained have the characteristics described above.
  • microparticles of example 1 are mixed with mannitol and aseptically filled into two chamber syringe (TCS) consisting of one compartment containing the microparticles and the mannitol and one compartment containing the vehicle for suspension of the microparticles.
  • TCS chamber syringe
  • the components of the vehicle are mixed together under inert atmosphere, e.g. nitrogen.
  • Example 3 Vehicle in ampoule and microparticles in vials:
  • the 480 mg microparticles corresponding to a 20 mg dose of octreotide acetate with 5 % loading of example 1 are suspended in 2.0 ml of a vehicle of composition A below in 6R vials.
  • the suspension is homogenized by shaking for about 30 seconds.
  • the reconstituted suspension may be injected without any issues using a 20 Gauge needle.
  • Example 4 Microparticles and vehicle in the DCS
  • 240 mg of microparticles of example 1 are reconstituted in 1 ml of the vehicle composition B, homogenized with a propeller mixer at 400 rpm for 1 to 12 hours and aseptically filled in the double chambers syringe then freeze-dried .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition comprises octreotide acetate microparticles of linear poly(lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.

Description

Pharmaceutical composition comprising microparticles
The present invention relates to pharmaceutical compositions, in particular to depot microparticles.
Octreotide acetate microparticles for injectable suspension are commercialized as pharmaceutical compositions under the brand name SANDOSTAΗN LAR. These pharmaceutical compositions are indicated for, inter alia, long-term maintenance therapy in acromegalic patients, and treatment of severe diarrhea and flushing associated with malignant carcinoid tumors and vasoactive intestinal peptide tumors (vipoma tumors). The pharmaceutical compositions are normally administered once-a-month. The octreotide is presented as a sterile pharmaceutical composition in a vial which when mixed with a vehicle for suspension such as sterile water becomes a suspension that is administered by an intragluteal injection.
The octreotide acetate microparticles are produced from the acetate salt of octreotide which is distributed throughout a biodegradable poly (DL-lactide-co-glycolide)-glucose star polymer (disclosed in e.g. US patent 5,922,682, the contents of which are incorporated herein by reference). The octreotide acetate microparticles are produced according to the teaching of US patent 5,538,739 (the contents of which are incorporated herein by reference) involving use of silicone oil and heptane. Traces of these starting materials may be detected in the final product.
Until now, no octreotide composition based on linear poly (lactide-co-glycolide) in sustained release form for parenteral administration has reached the market. The present invention provides a sustained release formulation of octreotide which is less expensive than the one available on the market and which is more easy to manufacture.
The present invention provides commercially acceptable octreotide acetate microparticles produced from linear poly (lactide-co-glycolide), hereinafter referred to as PLG, which have similar pharmacokinetic characteristics to SANDOSTAΗN LAR with acceptable drug loading whilst also of high purity and which may be free from silicone oil and heptane. Accordingly in one aspect the present invention provides i) a pharmaceutical composition comprising octreotide acetate microparticles of linear poly
(lactide-co-glycolide) polymer wherein the polymer contains less than 1% weight/weight silicone oil or heptane or ii) a pharmaceutical composition comprising octreotide acetate microparticles of linear poly
(lactide-co-glycolide) polymer wherein the polymer is free from silicone oil or heptane (both of which are hereinafter referred to microparticles of the invention).
In another aspect the present invention provides a process for the production of octreotide acetate microparticles, comprising the steps of: a) dissolving or dispersing octreotide acetate in methylene dichloride containing a dissolved linear poly (lactide-co-glycolide) to form a dispersion or a homogeneous solution; b) combining said dispersion with an effective amount of a continuous process medium to form an emulsion that contains said process medium and microdroplets comprising said octreotide acetate, said solvent and said linear poly (lactide-co-glycolide); and c) immediately after the formation of said emulsion, adding all at once said emulsion to an effective amount of an extraction medium to extract said solvent from said microdroplets to form said microparticles.
A- In another aspect, the present invention provides a process for the production of octreotide acetate microparticles, comprising the steps of: a) dispersing octreotide acetate in methylene chloride containing a dissolved linear poly (lactide-co-glycolide) to form a dispersion; b) combining said dispersion with an effective amount of a continuous process medium, to form an emulsion that contains said process medium, e.g water or preferably an aqueous buffered solution with a stabilizing agent, e.g. PNA, and microdroplets comprising said octreotide acetate, said solvent and said linear poly (lactide-co-glycolide); c) immediately after the formation of said emulsion, adding all at once said emulsion to an effective amount of an extraction medium, e.g. an aqueous phase, e.g. an aqueous solution of a stabilizing agent, e.g. polyvinylalcohol, to extract said solvent from said microdroplets to form said microparticles; and d) collecting and drying the microparticles, e.g. freeze-drying or drying under vacuum. B- The present invention provides a process for the production of octreotide acetate microparticles by a multiple emulsion process, the improvement which comprises the steps of: a) dissolving octreotide acetate in an aqueous solution, e.g. water or a buffered aqueous solution, emulsifying the octreotide acetate aqueous solution with methylene chloride containing a dissolved linear poly (lactide-co-glycolide) to form a water in oil emulsion; and b) emulsifying said emulsion with an aqueous solution, e.g. an aqueous solution containing a stabilizing agent, e.g. polyvinyl alcohol, and optionally at least one buffering salt, to form a water-in-oil-in-water double emulsion, , c) immediately after the formation of said double-emulsion, adding all at once said double-emulsion to an effective amount of an extraction medium, e.g. an aqueous phase, e.g. an aqueous solution of a stabilizing agent, e.g. polyvinylalcohol, to extract said solvent from said microdroplets to form said microparticles; and d) collecting and drying the microparticles, e.g. freeze-drying or drying under vacuum.
An aqueous solution of octreotide acetate may be used, preferably a water solution, which is then emulsified with the polymer solution to form an emulsion.
C- In a process for the production of octreotide acetate microparticles by an emulsion process, the improvement which comprises the steps of: a) mixing octreotide acetate in methanol with methylene chloride containing a dissolved linear poly (lactide-co-glycolide) to form a solution; and b) emulsifying said solution with the extraction medium, e.g. water or preferably an aqueous buffered solution with a stabilizer, e.g. PNA; c) immediately after the formation of said emulsion, adding all at once said emulsion to an effective amount of an extraction medium, e.g. an aqueous phase, e.g. an aqueous solution of a stabilizing agent, e.g. polyvinylalcohol, to extract said solvent from said microdroplets to form said microparticles; and d) collecting and drying the microparticles, e.g. freeze-drying or drying under vacuum.
According to this process C, octreotide acetate is preferably dissolved in a polar organic solvent miscible with methylene chloride, preferably methanol. The process may be effected as described above. The process medium of processes A, B and C can be, e.g. an aqueous phase, e.g. an aqueous solution of PNA, e.g. an aqueous solution of PNA and optionally at least one buffering salt. The process medium can be saturated with the same organic solvent as used to dissolve the polymer in order to stabilize the formation of the emulsion droplets and avoid a too fast extraction of the polymer solvent from the emulsion droplets.
In step a) of processes A, B and C, the PLG may be dissolved in any of the solvents suitable for PLG dissolution, e.g. ethylacetate, tetrahydrofurane, acetonitrile, methylene chloride, hexafluoroisopropanol, chloroform, acetone. For example, PLG may be dissolved in methylene chloride at a concentration of from about 1% to about 40%, typically about 2- 2.5% w/v.
In the processes A, B and C according to the invention, when the suitable solvent used to dissolve PLG is miscible with water, the suitable polymer solvent may be removed by extraction from the microparticles with water or with an aqueous solution as described above.
When the suitable solvent used to dissolve PLG is non- or poorly miscible with water then the polymer solvent may be eliminated by evaporation. Step a) would be identical as described in the processes A, B and C of the invention. But for step b), the dispersion or the solution or the emulsion prepared in step a) is mixed with high shear stress with a suitable quantity of process medium in the ratio of 1 volume of said dispersion or solution of step a) with 10 to up to 50 volumes of continuous medium. Then step c) would consist in hardening the microparticles by solvent evaporation under stirring, e.g. 200 rpm at room temperature with constant evacuation of solvent vapors, for 1 up to 10 hours , e.g. 5 hours with optionnaly a heating phase up to 40°C, preferably up to 52°C; and step d) would consist in washing the microparticles, e.g. in water, collecting and drying the microparticles, e.g. freeze-drying or drying under vacuum.
The processes may be effected in conventional manner, e.g. high speed stirrers may be used to produce emulsions. The concentration of octreotide acetate in polar organic solvent or in aqueous solution is preferably from about 1% to about 20% w/v, preferably about 4 to 10% w/v, more preferably about 4 to 7% w/v, even more preferably about 5% w/v. It is preferred to have a homogeneous solution after mixing of the octreotide with the dissolved linear poly (lactide-co- glycolide). Mixture of up to about 20% v/v of (i) a solution containing methanol with (ii) methylene chloride containing a dissolved linear poly (lactide-co-glycolide), e.g. with the concentration of poly(lactide-co-glycolide) in the organic solvent being not more than 20% w/v), may still result in a homogeneous solution, e.g. up to about 20% v/v of solution (i) in a mixture of (i) + (ii). The weight ratio of component (i) to component (ii) is typically about 1:8.
In step b) an emulsion may be produced by dispersing the octreotide acetate/PLG - methylene chloride mixture into an aqueous process medium. The continuous phase which is preferably saturated with the polymer solvent, e.g. methylene chloride.
Prior to the addition of the mixture containing the PLG/octreotide to the process medium, the process medium is preferably saturated with the suitable solvent of the polymer, e.g. methylene chloride to reduce extraction of solvent from the microdroplets during formation of the emulsion. The process medium is then mechanically agitated with devices such as homogenizers, propellers or the like, as the PLG/octreotide mixture is added to the process medium. During this step of the process, no solvent may be generally evaporated or removed from the microdroplets. The temperature at which the emulsion is formed is not particularly critical, except that it may be within a range that will prevent the methylene chloride from boiling or the process medium from gelling or freezing or the octreotide or PLG from degrading. The time required to form an emulsion is quite short. Generally, emulsions may be formed within 30 seconds to 5 minutes, depending upon the stabilizing agent, if any, used and the method of agitation of the process medium. Preferably, a stabilizing agent is present.
Preferably, a stabilizing agent for emulsions produced in microparticle processes is present to prevent agglomeration. The concentration present may affect the final size of the microparticles. Generally, the concentration of the emulsion stabilizing excipient in the process medium will be from 0.01% to about 20% w/v depending on the surfactant, the polymer solvent, and the process medium used. The amount of stabilizing agent is preferably from about 0.025 to about l%w/v. Suitable stabilizing agents include:
A) polyvinyl pyrrolidone: Suitably the molecular weight may vary between 2000 and 20000 daltons. Suitable examples include those commonly known as Povidone K12 F (average molecular weight about 2500 daltons), Povidone K15 (average molecular weight about 8000 daltons) or Povidone K17 (average molecular weight about 10000 daltons). Preferably, the polyvinyl pyrolidone is present in an amount of from about 0.1 to about 20% w/v, e.g. about 5% w/v.
B) carboxymethyl cellulose sodium (NaCMC): Preferably it has a low molecular weight. The viscosity may be, e.g. up to 20 cP or mPa s for a 2% aqueous solution or a viscosity of from 8 to 25 mPa s. Conveniently the degree of substitution is from aboutθ.5 to about 1.45, e.g. 1.15 to about 1.45, e.g. 0.7. Typically the sodium content is about 5 to about 12%, e.g. 10.5% to about 12%.
C) polyvinyl alcohol, herein after referred as PNA: In one embodiment, the polyvinyl alcohol has a molecular weight from about 10000 to about 150000, e.g. from about 10000 to about 90000 daltons, e.g. about 30000 daltons.
Conveniently, the polyvinyl alcohol has a low viscosity having a dynamic viscosity of from about 3 to about 9 mPa s when measured as a 4% aqueous solution at 20°C or by DIN 53015. Suitably, the polyvinyl alcohol may be obtained from hydrolyzing polyvinyl acetate. Preferably, the content of the polyvinyl acetate is from about 10 to about 90% of the polyvinyl alcohol. Conveniently the degree of hydrolysis is about 85 to about 89%. Typically the residual acetyl content is about 10 to 12 %. Preferred brands include Mowiol 4-88, Mowiol 8-88 and Mowiol 18-88 available from Clariant AG Switzerland. Preferably the polyvinyl alcohol is present in an amount of from about 0.1 to about 5%, e.g. 0.5% w/v.
D) gelatin: Preferably, the gelatin is porcine or fish gelatin. Conveniently, the gelatin has a viscosity of about 25 to about 35 cps for a 10% solution at 20°C.
Typically, pH of a 10% solution is from about 6 to about 7. A suitable brand has a high molecular weight, e.g. Norland high molecular weight fish gelatin obtainable from Norland Products Inc, Cranbury New Jersey USA. Preferably, the gelatin is present in an amount of from about 0.01 to about 5%, e.g. 0.5 % or 0.05%.
Conveniently, polyvinyl alcohol may be used.
In step c) transferring all of the emulsion immediately to a large volume of process medium or other suitable extraction medium to immediately extract the solvent from the microdroplets in the emulsion forms microparticles of the invention.
As soon as an emulsion forms, all of the process medium containing the organic microdroplets is transferred, as quickly as possible, to an extraction medium so that greater than 20% to 30% of the solvent may be immediately removed from the microdroplets, e.g. within 3 minutes. Normally, water is used as the extraction medium but other solvents or oils can also be used. In addition, salts may be added to the extraction medium to adjust its ionic strength or pH. The amount of extraction medium used may be somewhat critical in that sufficient medium must be present to allow approximately immediate extraction of the solvent out of the microdroplets. Accordingly, the volume of the extraction medium will depend on the solvent used to dissolve the wall material and its solubility in the extraction medium. Generally, the volume of the extraction medium should be at least the volume needed to dissolve all of the solvent out of the microdroplets, preferably a volume 10-fold or higher. In one embodiment, the added water is at a pH of about 7 or higher. Such pH may be adjusted to increase the encapsulation efficiency of the octreotide in the microparticles of the invention.
Preferably, an aqueous sodium dihydrogen phosphate/disodium hydrogen phosphate buffer solution is present
After extraction of all or almost all of the solvent from the microdroplets, e.g. generally within 15 to 30 minutes, the hardened microparticles may be collected by centrifugation, filtration, or the like.
In one embodiment, gelatin is not used and is absent in the microparticles of the invention.
The lactide may be D, L or mixtures thereof, e.g. racemic DL lactide.
Homopolymers, e.g. poly(DL-lactide) homopolymers, may be used. The molecular weight of the homopolymers is from about 7,000 to 25,000 daltons, e.g. 18 000 daltons. Preferably the polymer used is poly (DL-lactide-glycolide), herein after referred as PLG. The ratio of lactide to glycolide units in the PLG may vary between wide limits. It is however preferred to have a molar ratio of from 90 to 10 to 40:60 lactide to glycolide units, e.g. (i) 50:50 poly(lactide-glycolide) or (ii) 75:25 poly(lactide-glycolide) or (iii) 65:35 poly(lactide- glycolide).
The polymers may be pure poly(lactide-glycolide) polymers or copolymers with other units. Preferably they are pure poly(lactide-glycolide) polymers.
Typically, the average molecular weight of the PLG is from about 5,000 to about 70,000 daltons, e.g. 13 000, preferably it is from about 30,000 to about 70,000 daltons, especially from about 40,000 to about 60,000 daltons, more especially about 50,000 daltons. The inherent viscosity of the PLG may vary between wide limits. It is however preferred to be in the range from about 0.1 to about 0.8 dL/g, e.g. from about 0.2 to about 0.8 dL/g in hexafluoroisopropanol or preferably chloroform when measured under standard conditions, e.g. 20°C. A preferred example has a viscosity of from 0.45-0.55 dL/g in chloroform.
Preferably, the polymer is amorphous. The linear polymer of the invention is not a star polymer and contains less than 5%, or preferably is free from, star polymers, e.g. a reaction product of a polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 or a reactive derivative thereof and lactic acid or a reactive derivative thereof and glycolic acid or a functional derivative thereof. These star polymer products are disclosed, e.g. in US patent 5,922,682.
The linear polymers of the invention may be produced in conventional manner, e.g. using conventional techniques such as polycondensation and ring-opening of dimers. The production may be, e.g. according to the teachings of US patent 3,773,919 (the contents of which are hereby incorporated herein by reference). The polymer may be a reaction product of lactic acid or a reactive derivative thereof, e.g. D,L-lactide, and glycolic acid or a functional derivative thereof, e.g. glycolide. There may be present a suitable catalyst for the production of linear polymers for example zinc oxide, zinc carbonate, basic zinc carbonate, diethyl zinc, organotin compounds, for example stannous octoate (stannous 2-ethylhexanoate), tributylaluminium, titanium, magnesium or barium compounds or litharge. Stannous octoate (stannous 2-ethylhexanoate) is preferred. The polymer is preferably obtained from Birmingham Polymers Inc., Birmingham, Alabama, USA.
The octreotide acetate may be produced in conventional manner, e.g. as disclosed in US patent
4,395,403, the contents of which are incorporated herein by reference.
Insofar as any aspect of production of the microparticles of the invention are not disclosed herein, such production aspect may be effected in conventional manner or in a manner analogous to known methods.
The amount of octreotide on or near the surface and hence the initial drug burst may be reduced by briefly washing the microparticles of the invention with water, e.g. including a
1/15 molar acetate buffer at pH 4.0 during 5 minutes.
The microparticles of the invention may be dried, e.g. to remove water and other volatiles like methylene chloride.
In the drying step, the microparticles of the invention may be subjected, e.g. to:
1) a freeze-drying process or
2) vacuum of 10"2 to 50 millibars, e.g. 30 millibars or 0.1 mbar
3) addition of mannitol in powder to the filtered microparticles in a tumbler, under vacuum as in the drying process 2) and heating of 45°C to 55°C, preferably 48 to 54°C, most preferably 50 to 52°C.
The volatile solvent, e.g. methylene chloride, may alternatively be removed from the microparticles in suspension in aqueous solution, preferably a buffered water solution, e.g. potassium/sodium phosphate, optionally under vacuum conditions of the drying process 2.
Preferably, the microparticles of the invention may be purged with nitrogen or another inert gas. If desired the microparticles of the invention may be heated, e.g. from 25 to 55°C, preferably from 48 to 54°C. Duration of the drying period may be, e.g. from 2 hours to 5 days.
Hence, the present invention provides a process for the production of octreotide acetate microparticles by an emulsion process, which comprises the step of removing volatile solvents, e.g. methylene chloride.
The resultant microparticles may be free-flowing powders of spherical particles.
The microparticles of the invention contain preferably less than 1 % silicone oil, e.g. less than
0.5 or 0.1 %, preferably less than 0.05%, especially less than 0.01%, silicone oil. The microparticles of the invention include for example less than 0.5%, e.g. less than 0.2%, preferably less than 0.1%, methylene chloride.
The microparticles of the invention include for example less than 0.05%, e.g. less than 0.03%, preferably less than 0.01% especially less than 0.005% or 0.001%, methanol.
The microparticles of the invention include for example less than 3%, e.g. less than 1%, less than 0.1% preferably less than 0.05 or 0.01%, especially less than 0.005%, polyvinyl alcohol.
The microparticles of the invention include for example less than 2%, e.g. less than 1 or 2.%, preferably less than 0.1% heptane, especially less than 0.01% or 0.005% heptane.
The microparticles of this invention may have, e.g. a size range from about 1 to 250, preferably 10 to 200, especially 10 to 130 microns in diameter. Mean diameters may be, e.g. from 30 to 100 microns, e.g. from 30 to 90 microns, e.g. 80 to 100 microns. The size distribution of the microparticles of the invention has preferably at least one of the following average diameter characteristics:
99% or more smaller than 130 microns
90% or more smaller than 90 microns
80% or more smaller than 70 microns
95% or more greater than 10 microns based on the average size distribution as measured by conventional light scattering methods. It is preferred to have a broad size distribution of the microparticles of the invention.
The microparticles of the invention may exhibit a smooth to rough surface.
It is preferred to have a smooth surface in the microparticles of the invention. The smoothness may be determined in conventional manner, e.g. by visual determination by electron microscopy.
The microparticles of the current invention are usually made up of particles of a spherical shape, although microparticles may be irregularly shaped.
Preferably the surface area varies by about 5% from the corresponding surface area of a sphere.
Additionally the content uniformity of a unit dose is excellent. Unit doses may be produced which vary from about 85 to about 115%, e.g. from about 90 to about 110%, or from about
95 to about 105%, of the theoretical dose.
Preferably the microparticles of the invention are dense rather then porous. The porosity may be determined in conventional manner, e.g. by visual determination by BET-nitrogen-sorption / Hg-porosimetry or electron microscopy, e.g. by observing the diameter and extent of channels in a cut microparticle.
Preferably the microparticles of the invention contain less than 4 %, especially less than 3% and preferably less than 2% total octreotide degradation products.
The present invention also provides a pharmaceutical composition comprising microparticles of the invention.
The pharmaceutical composition may be in the dry state. Preferably, the pharmaceutical composition contains a vehicle to facilitate reconstitution. In one embodiment the the vehicle preferably comprises from about 1% to 40% of the pharmaceutical composition. In another embodiment of the invention the microparticles of the invention may comprise from about at least 90 % of the pharmaceutical composition.
A vehicle to facilitate reconstitution may be provided together with the pharmaceutical composition. The vehicle for reconstitution may be provided, e.g. in a separate vial or ampoule or in a separate chamber of a two chamber syringe, e.g. a two chamber syringe consisting of one compartment containing the microparticles and optionally an isotonizing agent, and optionally a surfactant and optionally a viscosity increasing agent, e.g. coated on the microparticles or present as a layer in the compartment containing the microparticles and one compartment containing the vehicle or an aqueous phase, e.g. water for injection, a buffered solution, e.g. a low molarity phosphate buffered solution at physiologic pH, if all the excipients of the vehicle are already in the chamber together with the microparticles, for suspension of the microparticles.
The microparticles of the invention are hydrophobic. When using water as a vehicle, the microparticles of the invention will not resuspend and they will float on the top of the aqueous phase. Therefore the problem is to find a vehicle to suspend the microparticles of the invention and suitable for injection.
To improve the wettability of the microparticles of the invention, a wetting-agent can be included into the vehicle to improve the capacity of the microparticles of the invention to be suspended in an aqueous medium. However, by increasing their wettability, the microparticles then have the drawback that they sediment. The vehicle may contain excipients, e.g. a viscosity-increasing agent and/or a wetting-agent. A vehicle for suspension may comprise a viscosity increasing agent and/or wetting agent as mentioned above and additionally water.
A suitable anti-agglomerating agent includes mannitol. Mannitol may also serve as a suitable isotonizing agent. If desired the pharmaceutical composition in the dry state may comprise an anti-agglomerating agent such as mannitol. Preferably, this is present in about2 to 10%, e.g. about 2-5%, e.g. 4% weight/weight of the microparticles in the dry state of the pharmaceutical composition.
The total concentration of the isotonizing agent corresponds to the concentration of the isotonizing agent when the microspheres are in suspension in the vehicle. The total concentration of isotonizing agent may be of from 1 to 50 mg/ml, e.g. 4 to 10 mg/ml, e.g. 5 to 8 mg ml, e.g. 6 mg ml. An anti-agglomerating agent can used in the pharmaceutical composition, i.e. the anti-agglomerating agent may be present in the dry state with the micropheres or may be present on the surface of the microspheres. If the agglomerating agent may be used as an isotonizing agent then the concentration of said isotonizing agent in the vehicle is calculated to so that the total concentration of isotonizing/anti-agglomerating agent in the vehicle with the microparticles in suspension in said vehicle may be in the range of from 1 to 50 mg ml, e.g. 4 to 10 mg/ml, e.g. 5 to 8 mg/ml, e.g. 6 mg/ml.
A suitable viscosity-increasing agent includes carboxymethyl cellulose sodium, herein after referred as NaCMC. NaCMC has a low viscosity. Embodiments may be as described above. Typically, NaCMC has a high molecular weight. The viscosity may be from about 1 to 30 mPa s, e.g. from 10 to about 15 mPa s when measured as a 1% (w/v) aqueous solution at 25°C in a Brookfield LVT viscometer with a spindle 1 at 60 rpm. Conveniently, the degree of substitution is of NaCMC from about 0.7 to about 1.45, e.g. from about 1.15 to about 1.45. Typically the sodium content of NaCMC is from about 5 to about 12%, e.g. about 10.5% to about 12%. NaCMC can be present in this is present in about 0.1-1%, e.g. 0.5% w/v of the vehicle composition. Said suitable viscosity-increasing agent can be present in a concentration of 1 to 30 mg ml in the vehicle, e.g. 7 mg/ml, 10 mg ml.
Preferably a wetting agent is present. Such wetting agents preferably include non-ionic surfactants. a) Poloxamers also known as polyoxyethylene polyoxypropylene block copolymers Preferably, the poloxamers of the invention are solid.
In one embodiment the molecular weight is from about 2000 to about 8000 daltons. The degree of polymerization of the ethylene moeity is typically 80 to about 110 units. The degree of polymerization of the propylene moiety is typically 20 to about 60 units. Examples of such compounds suitable for use in accordance with the present invention are those known and commercially available, e.g. under the trade name Pluronic F 68 available from BASF Germany. Pluronic F 68 can be present in the vehicle composition at a concentration of from 0.1 mg/ml to 5 mg ml. b) Polyoxyethylene-sorbitan-fatty acid esters e.g. mono- and trilauryl, palmityl, stearyl and oleyl esters e.g. of the type known and commercially available under the trade name TWEEN
20 [polyoxyethylene(20)sorbitanmonolaurate], 40 [polyoxyethylene(20)sorbitanmonopalmitate],
60 [polyoxyethylene(20)sorbitanmonostearate],
80 [polyoxyethylene(20)sorbitanmonooleate], 65 [polyoxyethylene (20 )sorbitantristearate] , 85 [polyoxyethylene(20)sorbitantrioleate],
21 [polyoxyethylene(4)sorbitanmonolaurate],
61 [polyoxyethylene(4)sorbitanmonostearate], and
81 [polyoxyethylene(5)sorbitanmonooleate].
Especially preferred products of this class for use in the pharmaceutical compositions of the invention are the above products TWEEN 20, TWEEN 40 and TWEEN 80. Such wetting agents are preferably present in about 0.01 to about 1% w/v, e.g. 0.1% w/v of the pharmaceutical composition. Said wetting agents may be present in about 0.01 to 5 mg/ml of the vehicle, e.g. 2 mg/ml.
The pharmaceutical composition may be stored under aseptic conditions, e.g. in a vial. All steps are conveniently effected under sterile conditions using sterile material, e.g. produced using sterile filters.
Microparticles of the present invention may be stored in the form of a powder. If desired a dry pharmaceutical composition and an aqueous medium vehicle for reconstitution may be housed separately in a double chamber syringe. For administration as injection the microparticles are suspended in a suitable vehicle for suspension, e.g. before administration to the patient. The amount of liquid vehicle for suspension is preferably about 0.5 to 5 ml, e.g. 1 to 5 ml, e.g. 1 ml per dose, 2 ml per dose. The liquid may be mixed with the dry pharmaceutical composition just prior to administration.
The vehicle according to the present invention comprises a wetting agent in a concentration of 0.1 mg/ml to 5 mg/ml and/or a viscosity-increasing agent present in a concentration of 1 to 30 mg/ml and
In the further aspect the invention provides a pharmaceutical composition comprising octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer admixed or in association with a non-ionic surfactant (herein these compositions are also referred to as compositions of the invention).
Excipients disclosed in the literature, as for instance in the components of the compositions of the invention may be described in Fiedler, H.P. "Lexikon der Hilfsstoffe fiir Pharmazie, Kosmetik und angrenzende Gebiete", Editio Cantor Verlag Aulendorf, Aulendorf, 4th revised and expanded edition (1996) Germany and "Handbook of Pharmaceutical Excipients", Edited by A.H. Kibbe, American Pharmaceutical Association, Third Edition (2000), as well as manufacturer's brochures, the contents of which are incorporated herein by reference, may be used in the pharmaceutical compositions according to the invention.
All percentages as used herein are weight by weight (w/w) except where otherwise specified.
The pharmaceutical compositions of the invention may be administered by intragluteal, intramuscular or subcutaneous injection. The pharmaceutical compositions of the invention administered by injection provide an effective treatment of diseases over an extended period, e.g. over 2 weeks to 6 months, e.g. over 2 weeks to 8 weeks, e.g. over 2 to 6 weeks. The microparticles allow a controlled release of octreotide by diffusion and therefore steady-state levels of the drug are obtained over the extended period.
The microparticles of the invention may be used for the same indications as known octreotide acetate microparticles. The exact dose of octreotide will depend on a number of factors, including the condition to be treated, the severity of the condition to be treated, the weight of the subject and the duration of therapy.
The exact dose of microparticles of the invention used will depend on a number of factors, including the rate of release of octreotide and the desired duration of treatment.
The amounts may be determined using standard animal and clinical tests, e.g. bioavailability tests using rabbits, using SANDOSTAΗN LAR as a standard. Octreotide levels may be determined using conventional methods, e.g. gas chromatography or high performance liquid chromatography. Typically for SANDOSTATIN LAR in humans an initial drug burst is seen, declining to a nadir in the next few days, followed by a plateau phase for 2 to 3 weeks post injection. For example at the 20 mg octreotide dose maximum serum concentrations of about
800 ng/1 may be reached from day 21 and last for 4 weeks.
If desired conventional in vitro tests may be used. In one such test SANDOSTAΗN LAR in acetate buffer pH 4 at 0.1 mM a continuous release profile is observed. Preferably pure water is used. Release characteristics of octreotide may be any of the following:
Not more than 1.5% of octreotide dose in one hour, e.g. at least 0.2%
Not more than 4% of octreotide dose in 4 hours; or
Not more than 7% of octreotide dose in 24 hours.
It is preferred to use single administration of the microparticles of the invention over 30 days.
The pharmaceutical compositions of the invention preferably include 10, 20 or 30 mg of octreotide.
Conveniently the loading of octreotide in the microparticles of the invention is from about 1 to about 50 %, e.g. 1 to about 50%, e.g. 1 to 7%, e.g. from about 3 to about 7%, typically 4 to 6 %, e.g. 5%.
The pharmaceutical compositions of the invention are useful for the treatment of a disease treatable by octreotide, e.g. acromegaly.
The present invention also provides: a) Use of the octreotide for the manufacture of microparticles or pharmaceutical compositions of the invention to be administered to a patient for the treatment of a disease treatable by octreotide, e.g. acromegaly. b) A method of administering of the octreotide, e.g. for the treatment of acromegaly, said method comprising administering to a patient in need of octreotide therapy microparticles or a pharmaceutical composition of the invention.
Following is a description by way of example only of depot formulations of this invention.
Example 1: Microparticles
Step a): Approximately 2.5 g of poly(DL-lactide-co-glycolide) [polymer] are dissolved in 25 g methylene chloride to prepare a 9 wt. % polymer solution. After the polymer is completely dissolved, 188 mg octreotide acetate [drug] in 3.7 g methanol are added and allowed to dissolve.
Step b): This polymer/drug solution is then poured into a 1-L vessel containing 400 g of 5.0 wt. % polyvinyl alcohol (PVA). The PNA is stirred at about 750 rpm by a 2.5 inch impeller (e.g. TEFLON driven by a Fisher Stedi-speed motor). The PVA is also saturated with 7 ml of methylene chloride prior to the addition of the polymer/drug solution. The resulting emulsion is allowed to stir for 7 min.
Step c): The vessel contents are transferred all at once to 12.0 litres of stirred deionized water. The microparticles are stirred in the deionized water for approximately 30 min and then were collected over 45-μm mesh size meter and 212-μm mesh size stainless steel mesh steel sieves arranged in series. The microparticles are rinsed with additional deionized water and allowed to air dry.
The microparticles of the invention obtained have the characteristics described above.
Example 2
Vehicle composition
The microparticles of example 1 are mixed with mannitol and aseptically filled into two chamber syringe (TCS) consisting of one compartment containing the microparticles and the mannitol and one compartment containing the vehicle for suspension of the microparticles. Vehicle composition: mg/ml mg/ml
Pluronic F68 2.0 2.0
Sodium-carboxymethylcellulose 10.0 10.0
(Blanose 7LFD)
Mannitol 6.0 12.0
Water for injections ad 2.0 ml ad 2.0 r
The components of the vehicle are mixed together under inert atmosphere, e.g. nitrogen. The vehicle for a 10 mg dose of octreotide in the microparticles of the invention for a dry pharmaceutical composition. 2 ml of vehicle are provided.
Example 3: Vehicle in ampoule and microparticles in vials:
The 480 mg microparticles corresponding to a 20 mg dose of octreotide acetate with 5 % loading of example 1 are suspended in 2.0 ml of a vehicle of composition A below in 6R vials. The suspension is homogenized by shaking for about 30 seconds. The reconstituted suspension may be injected without any issues using a 20 Gauge needle.
Vehicle composition A: mg
Pluronic F68 2.0
Sodium-carboxymethylcellulose 7.0
(Blanose 7LFD)
Mannitol 45.0
Water for injections ad 1.0 ml
Example 4: Microparticles and vehicle in the DCS
240 mg of microparticles of example 1 are reconstituted in 1 ml of the vehicle composition B, homogenized with a propeller mixer at 400 rpm for 1 to 12 hours and aseptically filled in the double chambers syringe then freeze-dried .
Reconstitution of the microparticle lyophilisates with 1 ml pure water (WBU) resulted in fast and good wetting of the microparticles that may be injected without any issues using a 20 Gauge needle. Vehicle composition B mg Pluronic F68 2.0
Sodium-carboxymethylcellulose 17.5
(Blanose 7LFD)
Mannitol 36.0
Water for injections ad 1.0 ml

Claims

Claims
1. A pharmaceutical composition comprising octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane, preferably free from silicone oil or heptane.
2. A pharmaceutical composition comprising octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer admixed or in association with a vehicle comprising a non-ionic surfactant.
3. A pharmaceutical composition according to claim 1 or 2 further comprises an anti- agglomerating agent.
4. A process for the production of octreotide acetate microparticles, comprising the steps of: a) dissolving or dispersing octreotide acetate in methylene chloride containing a dissolved linear poly (lactide-co-glycolide) to form a dispersion; b) combining said dispersion with an effective amount of a continuous process medium to form an emulsion that contains said process medium and microdroplets comprising said octreotide acetate, said solvent and said linear poly (lactide-co-glycolide); and c) immediately after the formation of said emulsion, adding all at once said emulsion to an effective amount of an extraction medium to extract said solvent from said microdroplets to form said microparticles.
5. A process for the production of octreotide acetate microparticles by an multiple emulsion process, the improvement which comprises the steps of: a) dissolving octreotide acetate in water, emulsifying the octreotide acetate aqueous solution with methylene chloride containing a dissolved linear poly (lactide-co-glycolide) to form a water in oil emulsion; and b) emulsifying said emulsion with water.
6. Octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer obtainable by the process according to claim 4 or 5.
7. A pharmaceutical composition according to claim 1, 2 or 3 comprising microparticles according to claim 6 together with a vehicle comprising a wetting-agent and a viscosity increasing agent.
8. The pharmaceutical composition according to claim 7 wherein the wetting agent of the vehicle if Pluronic F 68.
9. The pharmaceutical composition according to claim 7 wherein the vehicle further comprises an isotonizing agent.
10. A commercial package comprising a pharmaceutical composition according to claim 1, 2 or 7.
PCT/EP2003/012898 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles WO2004045633A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020057008892A KR101146471B1 (en) 2002-11-19 2003-11-18 Pharmaceutical Composition Comprising Octreotide Microparticles
BR0316421-7A BR0316421A (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles
MXPA05005388A MXPA05005388A (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles.
JP2004552645A JP2006514927A (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles
KR1020127001817A KR101240071B1 (en) 2002-11-19 2003-11-18 Pharmaceutical Composition Comprising Octreotide Microparticles
CA2501978A CA2501978C (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles
EP03789053A EP1565161A2 (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles
AU2003293700A AU2003293700A1 (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles
NO20052952A NO20052952L (en) 2002-11-19 2005-06-16 Pharmaceutical composition comprising microparticles
AU2008200018A AU2008200018B2 (en) 2002-11-19 2008-01-03 Pharmaceutical composition comprising octreotide microparticles
AU2011200966A AU2011200966B2 (en) 2002-11-19 2011-03-04 Pharmaceutical composition comprising octreotide microparticles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0226993.4 2002-11-19
GB0226993A GB0226993D0 (en) 2002-11-19 2002-11-19 Organic compounds
GB0227883A GB0227883D0 (en) 2002-11-29 2002-11-29 Organic compounds
GB0227883.6 2002-11-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP11173962.9A Previously-Filed-Application EP2377519B1 (en) 2002-11-19 2003-11-18 Pharmaceutical Composition Comprising Octreotide Microparticles

Publications (2)

Publication Number Publication Date
WO2004045633A2 true WO2004045633A2 (en) 2004-06-03
WO2004045633A3 WO2004045633A3 (en) 2005-01-13

Family

ID=32299717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/012898 WO2004045633A2 (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles

Country Status (17)

Country Link
US (6) US20040097419A1 (en)
EP (2) EP1565161A2 (en)
JP (2) JP2006514927A (en)
KR (2) KR101146471B1 (en)
AU (3) AU2003293700A1 (en)
BR (1) BR0316421A (en)
CA (1) CA2501978C (en)
CO (1) CO5690533A2 (en)
EC (1) ECSP055800A (en)
ES (1) ES2577613T3 (en)
HK (1) HK1161123A1 (en)
MX (1) MXPA05005388A (en)
NO (1) NO20052952L (en)
PL (1) PL376015A1 (en)
PT (1) PT2377519E (en)
RU (2) RU2404748C2 (en)
WO (1) WO2004045633A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1787658A1 (en) 2005-11-10 2007-05-23 South Shore Properties Inc. Sustained release formulations of somatostatin analogue inhibitors of growth hormone
JP2008524235A (en) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． Sustained release delivery formulation for octreotide compounds
WO2010033776A1 (en) * 2008-09-18 2010-03-25 Surmodics Pharmaceuticals, Inc. Microencapsulation process with solvent and salt
US20100272820A1 (en) * 2006-11-27 2010-10-28 Dongkook Pharmaceutical Co., Ltd. Preparation Method of Sustained-Release Microcapsules Having Good Initial Burst Inhibiting Property and the Microcapsules Thereby
US7964219B2 (en) * 2004-08-12 2011-06-21 Qps, Llc Pharmaceutical compositions for controlled release delivery of biologically active compounds
US20160022764A1 (en) * 2013-03-15 2016-01-28 Rhythm Metabolic, Inc. Pharmaceutical compositions
WO2019155396A1 (en) * 2018-02-07 2019-08-15 Dr. Reddy's Laboratories Limited Sustained release microspheres with low initial burst and methods of preparation thereof
EP3785704A4 (en) * 2018-04-23 2022-05-04 HLB Pharmaceutical Co., Ltd Method for preparing biodegradable microsheres using stabilized single-phase mixed solution

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570960C (en) 2004-06-17 2013-10-01 Valera Pharmaceuticals, Inc. Compositions and methods for treating central precocious puberty
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
KR20130024987A (en) * 2005-12-22 2013-03-08 노파르티스 아게 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
KR100722607B1 (en) 2006-05-11 2007-05-28 주식회사 펩트론 A process of preparing microspheres for sustained release having improved dispersibility and syringeability
RU2463079C2 (en) * 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Separation agents for implanted device and methods for using them
MX2011000036A (en) 2008-06-25 2011-02-22 Endo Pharmaceuticals Solutions Octreotide implant having a release agent.
JP5622725B2 (en) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． Sustained delivery of exenatide and other polypeptides
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
CN106727448B (en) * 2016-12-12 2020-10-13 广州中大南沙科技创新产业园有限公司 Octreotide acetate dry powder inhalation preparation and preparation method thereof
JP7170670B2 (en) 2017-02-27 2022-11-14 ユニヴァーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイアー エデュケイション Antipsychotic composition and method of treatment
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0469520A2 (en) * 1990-08-01 1992-02-05 Sandoz Ag Polyactide preparation and purification
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE2512T1 (en) 1979-11-27 1983-03-15 Sandoz Ag POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE POLYPEPTIDES AND THEIR USE.
DE3032345C2 (en) * 1980-08-28 1984-06-28 Mathias 4815 Schloss Holte Mitter Storage of a doctor blade with bearings arranged laterally outside the stencil of a screen printing unit
CH656884A5 (en) 1983-08-26 1986-07-31 Sandoz Ag POLYOLESTERS, THEIR PRODUCTION AND USE.
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
AU5741590A (en) * 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9805417D0 (en) * 1998-03-14 1998-05-06 Core Technologies Limited Production of microparticles
US6204308B1 (en) * 1999-03-01 2001-03-20 Novartis Ag Organic compounds
ES2169980B1 (en) * 1999-12-17 2003-11-01 Lipotec Sa MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS.
AU2002232824A1 (en) * 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
EP0469520A2 (en) * 1990-08-01 1992-02-05 Sandoz Ag Polyactide preparation and purification

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1565161A2 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964219B2 (en) * 2004-08-12 2011-06-21 Qps, Llc Pharmaceutical compositions for controlled release delivery of biologically active compounds
JP2008524235A (en) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． Sustained release delivery formulation for octreotide compounds
EP1787658A1 (en) 2005-11-10 2007-05-23 South Shore Properties Inc. Sustained release formulations of somatostatin analogue inhibitors of growth hormone
US20100272820A1 (en) * 2006-11-27 2010-10-28 Dongkook Pharmaceutical Co., Ltd. Preparation Method of Sustained-Release Microcapsules Having Good Initial Burst Inhibiting Property and the Microcapsules Thereby
US8541030B2 (en) * 2006-11-27 2013-09-24 Dongkook Pharmaceutical Co., Ltd. Preparation method of sustained-release microcapsules having initial burst inhibiting property and the microcapsules thereby
WO2010033776A1 (en) * 2008-09-18 2010-03-25 Surmodics Pharmaceuticals, Inc. Microencapsulation process with solvent and salt
US10821080B2 (en) 2008-09-18 2020-11-03 Evonik Corporation Microencapsulation process with solvent and salt
US20160022764A1 (en) * 2013-03-15 2016-01-28 Rhythm Metabolic, Inc. Pharmaceutical compositions
US11129869B2 (en) * 2013-03-15 2021-09-28 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
WO2019155396A1 (en) * 2018-02-07 2019-08-15 Dr. Reddy's Laboratories Limited Sustained release microspheres with low initial burst and methods of preparation thereof
EP3785704A4 (en) * 2018-04-23 2022-05-04 HLB Pharmaceutical Co., Ltd Method for preparing biodegradable microsheres using stabilized single-phase mixed solution
US11633360B2 (en) 2018-04-23 2023-04-25 HLB Pharmaceutical Co., Ltd Method for preparing biodegradable microspheres using stabilized single-phase mixed solution

Also Published As

Publication number Publication date
CA2501978A1 (en) 2004-06-03
CA2501978C (en) 2013-12-17
MXPA05005388A (en) 2005-08-03
KR101146471B1 (en) 2012-05-21
HK1161123A1 (en) 2012-08-24
PL376015A1 (en) 2005-12-12
RU2010144614A (en) 2012-05-10
US20220273574A1 (en) 2022-09-01
AU2011200966A1 (en) 2011-03-24
KR101240071B1 (en) 2013-03-06
RU2404748C2 (en) 2010-11-27
NO20052952L (en) 2005-08-15
KR20050086708A (en) 2005-08-30
EP1565161A2 (en) 2005-08-24
JP5784402B2 (en) 2015-09-24
US20040097419A1 (en) 2004-05-20
US20200009056A1 (en) 2020-01-09
PT2377519E (en) 2016-06-09
US20140323415A1 (en) 2014-10-30
JP2006514927A (en) 2006-05-18
AU2003293700A1 (en) 2004-06-15
JP2011256185A (en) 2011-12-22
EP2377519A3 (en) 2011-11-23
AU2011200966B2 (en) 2013-08-01
AU2008200018B2 (en) 2010-12-09
AU2008200018A1 (en) 2008-01-31
RU2005119632A (en) 2006-05-10
WO2004045633A3 (en) 2005-01-13
EP2377519A2 (en) 2011-10-19
US20070122485A1 (en) 2007-05-31
KR20120032537A (en) 2012-04-05
US20170281548A1 (en) 2017-10-05
NO20052952D0 (en) 2005-06-16
ECSP055800A (en) 2005-08-11
EP2377519B1 (en) 2016-03-23
ES2577613T3 (en) 2016-07-15
CO5690533A2 (en) 2006-10-31
BR0316421A (en) 2005-10-11

Similar Documents

Publication Publication Date Title
AU2011200966B2 (en) Pharmaceutical composition comprising octreotide microparticles
JP6178772B2 (en) Sustained release formulation comprising octreotide and two or more polylactide coglycolide polymers
ZA200502748B (en) Pharmaceutical composition comprising octreotide microparticles.
WO2007147861A2 (en) Sustained release formulations of aromatase inhibitors
AU2013204972B2 (en) Pharmaceutical composition comprising octreotide microparticles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003789053

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/02748

Country of ref document: ZA

Ref document number: 200502748

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2501978

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 168342

Country of ref document: IL

Ref document number: 539765

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003293700

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500860

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 376015

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 20038A32495

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 936/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004552645

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057008892

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/005388

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 05050166

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1200500827

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2005119632

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2003789053

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057008892

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0316421

Country of ref document: BR